Development of an enzymatic pretargeting strategy for dual-modality imaging

Chem Commun (Camb). 2015 Mar 7;51(19):4055-8. doi: 10.1039/c4cc10265g.


A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / metabolism*
  • Cell Line, Tumor
  • Halogens / metabolism*
  • Humans
  • Hydrolases / metabolism*
  • Ligands
  • Optical Imaging / methods*
  • Tomography, Emission-Computed, Single-Photon / methods*
  • Trastuzumab


  • Antibodies, Monoclonal, Humanized
  • Halogens
  • Ligands
  • Hydrolases
  • Trastuzumab